Treatment schedules. (A) Assessment of the survival. AcSDKP was administred SC, either as a continuous infusion delivered by minipumps (dark ellipses) or as six injections (dark rectangles) beginning either 24 or 48 hours before the first DOX injection. Unless stated otherwise, the total dose of AcSDKP was 7.2 μg/mouse (approximately 360 μg/kg). DOX was given IP at a dose of 2.65 mg/kg/injection twice on the first day and once on the second, to yield a total dose of 7.95 mg/kg. (B) Evaluation of the recovery of progenitors, HPP-CFC and CFU-S. AcSDKP was administered SC as a continuous infusion delivered by minipump beginning 48 hours before the first injection of DOX. The total AcSDKP dose was always 7.2 μg/mouse. (C) Assessment of LTRC survival. AcSDKP was delivered by minipump 48 hours before the first DOX injection. On day 7, male mouse bone marrow was grafted into irradiated female recipients. (D) Combination of AcSDKP with G-CSF. AcSDKP was administered as six injections beginning 48 hours before DOX treatment. G-CSF was injected IP once a day at either 100, 300, or 500 ng/injection/mouse (approximately 5, 15, or 25 μg/kg) for 4 days, beginning on day 3.